Evidence map›Paper›PMID 15937202›Full record

ReviewPostgraduate medical journal2005

Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.

R Katira, A Chauhan, R S More

Abstract readReview
In one paragraph

Review in Postgraduate medical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

R KatiraDepartment of Cardiology, Victoria Hospital, Whinney Heys Road, Blackpool FY3 8NR, UK. Ravish@katira.wanadoo.co.uk
A Chauhan
R S More

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithrombotic agents have verified efficacy in reducing the thromboembolic risk associated with atrial fibrillation. This article focuses on the emergence of a new oral direct thrombin inhibitor, ximelagatran, into the arena of atrial fibrillation thromboprophylaxis. This review does not cover atrial fibrillation in the context of valvular heart disease. The efficacy of aspirin and warfarin will be discussed briefly.

Indexed as

Administration, OralAnticoagulantsAspirinAtrial FibrillationAzetidinesBenzylaminesChemical and Drug Induced Liver InjuryClinical Trials, Phase III as TopicHumansPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRisk FactorsStrokeThrombinThromboembolismWarfarinAnticoagulantsAspirinAzetidinesBenzylaminesPlatelet Aggregation InhibitorsThrombinWarfarinximelagatran

Identifiers

PMID15937202
PMCPMC1743289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.